Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
批准号:
7686218
负责人:
BRIAN R GASTMAN
金额:
$31.13万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-11 至 2013-07-31
关键词:
Active ImmunotherapyApoptosisApoptoticAreaBindingCD28 geneCD8B1 geneCancer PatientCell Culture TechniquesCellsClinicalCoinDataDevelopmentDiagnosticDiseaseEffector CellEtiologyFailureFamily memberFibroblastsFunctional disorderFutureGenerationsGoalsGrantHead and Neck Squamous Cell CarcinomaHead and neck structureHumanImmuneImmune responseImmune systemImmunologyImmunosuppressionImmunotherapeutic agentImmunotherapyIn VitroInterleukin-12Interleukin-2Interleukin-7LymphocyteMCL1 proteinMalignant NeoplasmsMature T-LymphocyteMediatingModelingMolecularMorbidity - disease ratePassive ImmunotherapyPathogenesisPatientsPatternPeripheral Blood LymphocytePhenotypePopulationProcessProteinsProtocols documentationQuality of lifeRegulationResearchRoleSamplingSignal TransductionSiteSolid NeoplasmSquamous cell carcinomaSuppressor-Effector T-LymphocytesT-LymphocyteTP53 geneTelomere ShorteningTestingTherapeuticTimeTranslationsTreatment ProtocolsTumor Cell LineUnited StatesUp-Regulationalternative treatmentanticancer researchbasecytokinedesignimprovedin vitro Modelin vivomelanomamortalitynovelnovel diagnosticsoutcome forecastpublic health relevanceresponsesenescencesuccesstumortumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Squamous cell carcinoma of the head and neck (SCCHN) remains one of the deadliest cancers in the United States. Despite many emerging new treatments there has been almost no success in improving either the morbidity or mortality of this disease. Continuing advances in immunology make immunotherapy an active area for current and future cancer research. However, the design of immunotherapeutic strategies for SCCHN requires an understanding of the tumor microenvironment. We have recently observed that a senescence-like process is involved in the dysfunction of T lymphocytes in the tumor microenvironment. Further, these cells not only have senescent features, but in addition have functional changes consistent with suppressor cells. Future success of immunotherapeutic approaches for cancer patients are dependent on the protection of T cells from such changes at the tumor site and the enhancement of their efficiency. Mcl-1, a prosurvival Bcl-2 family member, has recently been demonstrated to be required for the survival of mature T lymphocytes. Our preliminary results suggest that Mcl-1 may have a key regulatory role in the protection of T lymphocytes from tumor-induced senescence that is mediated through the pro-senescent and -apoptotic molecule, p53. Noteworthy, among the pro-survival Bcl-2 family members, Mcl-1 is the major protein to undergo significant upregulated expression in response to cytokines used for immunotherapy, such as, IL-2, IL-7, and IL-12. The current application will attempt to elucidate the role and functional mechanisms of Mcl-1 in the protection of SCCHN-associated lymphocytes from senescence at the tumor microenvironment. The underlying scientific approach will employ a model of tumor-induced senescence of T cells to further characterize the mechanisms involved in this process with an emphasis on the regulation of p53 senescent activity by Mcl-1. Further characterization of the suppressor function of these senescent T cells will be performed to better understand the impact of this process on the immune system. The translational components of this proposal will evaluate the diagnostic potential of the newly identified senescent suppressor T cells and elucidate intracellular targets for the improvement of current immunotherapeutic protocols for SCCHN. PUBLIC HEALTH RELEVANCE: Project Narrative The goal of the current project is to elucidate a new form of tumor immune evasion. By gaining a better understanding of the molecular mechanisms involved in the formation of cancer associated dysfunctional T cells new diagnostic and therapeutic regimens can be devised. The proposal centers on explaining how cancer in part evades the immune system through directly altering T cells with the goal of improving the success of emerging immune based therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of nuclear Mcl-1 mediated chemoresistance
-
批准号:10312133
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2020
-
负责人:BRIAN R GASTMAN
-
依托单位:
Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
-
批准号:8234371
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2011
-
负责人:BRIAN R GASTMAN
-
依托单位:
Tumor induced senescent and suppressor T cells - a novel mechanism of immune evas
-
批准号:8121606
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2011
-
负责人:BRIAN R GASTMAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: